Drug Class Detail

Drug Class VEGFR1 Inhibitor


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Semaxanib SU5416 FLT3 Inhibitor 48 VEGFR1 Inhibitor 4 VEGFR2 Inhibitor 34 Semaxanib (SU5416) is an inhibitor of FLT1 (VEGFR1), KDR (VEGFR2), and FLT3, which inhibits tumor vascularization and growth (PMID: 9892193, PMID: 12351406).
Brivanib BMS-540215 FGFR1 Inhibitor 21 VEGFR1 Inhibitor 4 VEGFR2 Inhibitor 34 Brivanib (BMS-540215) selectively binds and inhibits KDR (VEGFR2), while demonstrating moderate activity against VEGFR1 and FGFR1, which inhibits tumor angiogenesis, tumor cell growth, and induces tumor regression (PMID: 18829493, PMID: 16570908).
MK2461 MET Inhibitor 50 PDGFR Inhibitor (Pan) 27 RON Inhibitor 10 VEGFR1 Inhibitor 4 MK2461 inhibits wild-type and activated forms of MET, and also has activity against VEGFR1 (FLT1), MST1R (RON), and PDGFR resulting in inhibition of downstream signaling and decreased tumor growth (PMID: 20145145).
Cediranib AZD-2171|Recentin KIT Inhibitor 48 VEGFR1 Inhibitor 4 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Cediranib (AZD-2171) is an ATP-competitive inhibitor of all three vascular endothelial growth factor receptors (FLT1, KDR, and FLT4) and KIT, thereby blocking VEGF-signaling, angiogenesis, and tumor cell growth (PMID: 15899831, PMID: 24714778).
Molecular Profile Protein Effect Treatment Approaches